Drug ID:Drug164
Drug Name:GED-0301
CID:121490254
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT02601300, , NCT02596893
Molecular Formula:C200H261N69O107P20S20
Molecular Weight:6604.0 g/mol
Isomeric SMILES:CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3CO)N4C=NC5=C4N=C(NC5=O)N)OP(=S)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=C(C(=NC7=O)N)C)OP(=S)(O)OC[C@@H]8[C@H](C[C@@H](O8)N9C=NC1=C9N=C(NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC
Synonyms:mongersen; 1443994-46-4; UNII-O1VIU3R1NE; O1VIU3R1NE; DNA, d(P-thio)(G-T-m5C-G-C-C-C-C-T-T-C-T-C-C-C-m5C-G-C-A-G-C); GED-0301; GTPL8277; GED0301; DA-75665
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

No molecular structure data available

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT02974322 A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease PHASE3 WITHDRAWN Celgene Crohn Disease DRUG: GED-0301|DRUG: Placebo Details
NCT02685683 Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease PHASE2 TERMINATED Celgene Crohn's Disease DRUG: GED-0301 Details
NCT02641392 A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease PHASE3 TERMINATED Celgene Crohn's Disease DRUG: GED-0301|OTHER: Placebo Details
NCT02601300 An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis PHASE2 COMPLETED Celgene Colitis, Ulcerative DRUG: GED-0301 Details
NCT02596893 Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease PHASE3 TERMINATED Celgene Crohn Disease DRUG: GED-0301|DRUG: Placebo Details
NCT02367183 A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease PHASE1 COMPLETED Celgene Crohn Disease DRUG: GED-0301|DRUG: Placebo Details
NCT03467841 Cytomegalovirus Infection in Steroid-refractory Ulcerative Colitis NULL UNKNOWN Dr mohammedRmadan hamad Cmv Colitis DEVICE: CMV IgM, IgG in blood real time PCR for s… Details
NCT03272152 Comprehensive DNA Methylation Profiling in Crohn's Disease NULL UNKNOWN Jinling Hospital, China Crohn Disease|Methylation|Illumina Human Methylat… GENETIC: Genome-wide DNA methylation Details
NCT03266068 Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders NULL COMPLETED Mayo Clinic Campylobacter Infections|Irritable Bowel Syndrome GENETIC: DNA Analysis of Blood Sample|PROCEDURE: … Details
NCT03172195 Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up NA TERMINATED Centre Hospitalier Universitaire de Saint Etienne Colitis, Ulcerative PROCEDURE: rectosigmoidoscopy|BIOLOGICAL: biopsie… Details
NCT02984059 Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease NULL COMPLETED Connecticut Children's Medical Center Inflammatory Bowel Disease GENETIC: Genomic DNA|GENETIC: RNA analysis|GENETI… Details
NCT02503696 Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) NULL COMPLETED Exact Sciences Corporation Inflammatory Bowel Disease|Colorectal Neoplasms|D… DEVICE: Stool Collection Kit Details
NCT02128503 Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease NA TERMINATED Chinese University of Hong Kong Inflammatory Bowel Disease|Crohn Disease|Ulcerati… OTHER: HBV DNA level monitoring Details
NCT01860963 Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls NA COMPLETED Stanford University Anal Squamous Intraepithelial Lesion (ASIL)|HPV D… PROCEDURE: Anal Pap smear and HPV DNA testing Details
NCT01819766 Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease NULL COMPLETED Exact Sciences Corporation Inflammatory Bowel Disease (IBD)|Primary Sclerosi… None Details
NCT01793168 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NULL RECRUITING Sanford Health Rare Disorders|Undiagnosed Disorders|Disorders of… None Details
NCT01653054 Anal Dysplasia in Patients With Inflammatory Bowel Disease NA COMPLETED Montefiore Medical Center IBD PROCEDURE: Anal Pap Smear, HPV DNA Testing Details
NCT01028898 Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome NULL UNKNOWN Chinese PLA General Hospital Irritable Bowel Syndrome|Digestive System Disease… None Details
NCT00511329 Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease PHASE2|PHASE3 TERMINATED Nationwide Children's Hospital Arthritis, Juvenile Rheumatoid|Crohn Disease DRUG: somatropin [rDNA origin] for injection Details
ISRCTN30255103 Colorectal cancer screening by quantitative analysis of DNA isolated from exfoliated cells sampled from the surface of human rectal mucosa: A pilot study NULL Not Recruiting Colonix Medical Ltd (UK) Colorectal cancer; inflammatory bowel disease Can… This study was conducted with two distinct groups… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S08 Strengthening barrier function Modulation of barrier function phosphatidylcholine (lecithin); imiquimod; mongersen Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… Details

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study

PMID: 31850931
Year: 2020
Relationship Type: Treatment Score: 8.5

INTRODUCTION: The objective was to assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease …

Impact of patient characteristics on the clinical efficacy of mongersen (GED-03…

PMID: 26766141
Year: 2016
Relationship Type: Treatment Score: 7.3

BACKGROUND: In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting Smad7, was effective in inducing clinical remission in approxi…

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients…

PMID: 28847751
Year: 2018
Relationship Type: Mechanism Score: 6.3

Infectious bursal disease (IBD) is an economically important disease of young chickens caused by an Avibirnavirus, the infectious bursal disease vir…